title: DNA2 and EXO1 in replication-coupled, homology-directed repair and in the interplay between HDR and the FA/BRCA network.
abstract: During DNA replication, stalled replication forks and DSBs arise when the replication fork encounters ICLs (interstrand crosslinks), covalent protein/DNA intermediates or other discontinuities in the template. Recently, homologous recombination proteins have been shown to function in replication-coupled repair of ICLs in conjunction with the Fanconi anemia (FA) regulatory factors FANCD2-FANCI, and, conversely, the FA gene products have been shown to play roles in stalled replication fork rescue even in the absence of ICLs, suggesting a broader role for the FA network than previously appreciated. Here we show that DNA2 helicase/nuclease participates in resection during replication-coupled repair of ICLs and other replication fork stresses. DNA2 knockdowns are deficient in HDR (homology-directed repair) and the S phase checkpoint and exhibit genome instability and sensitivity to agents that cause replication stress. DNA2 is partially redundant with EXO1 in these roles. DNA2 interacts with FANCD2, and cisplatin induces FANCD2 ubiquitylation even in the absence of DNA2. DNA2 and EXO1 deficiency leads to ICL sensitivity but does not increase ICL sensitivity in the absence of FANCD2. This is the first demonstration of the redundancy of human resection nucleases in the HDR step in replication-coupled repair, and suggests that DNA2 may represent a new mediator of the interplay between HDR and the FA/BRCA pathway.
authors.affiliation: Braun Laboratories, California Institute of Technology, Pasadena, CA, USA.
authors.forename: Kenneth K
authors.initials: KK
authors.lastname: Karanja
authors.forename: Stephanie W
authors.initials: SW
authors.lastname: Cox
authors.forename: Julien P
authors.initials: JP
authors.lastname: Duxin
authors.forename: Sheila A
authors.initials: SA
authors.lastname: Stewart
authors.forename: Judith L
authors.initials: JL
authors.lastname: Campbell
mesh_terms: D000970:Antineoplastic Agents / Q000633:toxicity; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000633:toxicity; D004249:DNA Damage / Q000187:drug effects; D004265:DNA Helicases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D004260:DNA Repair; D045643:DNA Repair Enzymes / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D005090:Exodeoxyribonucleases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D005199:Fanconi Anemia / Q000378:metabolism / Q000473:pathology; D052236:Fanconi Anemia Complementation Group D2 Protein / Q000378:metabolism; D005260:Female; D042822:Genomic Instability / Q000187:drug effects; D057809:HEK293 Cells; D006801:Humans; D034622:RNA Interference; D034741:RNA, Small Interfering; D054875:Ubiquitination
chemical_list: D000970:Antineoplastic Agents; D052236:Fanconi Anemia Complementation Group D2 Protein; D034741:RNA, Small Interfering; C114331:EXO1 protein, human; D005090:Exodeoxyribonucleases; D004265:DNA Helicases; C509908:DNA2 protein, human; D045643:DNA Repair Enzymes; D002945:Cisplatin